Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3.
Saved in:
| Title: | Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3. |
|---|---|
| Authors: | Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Verschraegen C; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States., Sigal D; Scripps Clinic and Scripps Cancer Center, La Jolla, CA, United States., Lenz HJ; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States., Hochster H; Rutgers Cancer Institute, New Brunswick, NJ, United States., Baysal MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Chakraborty A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Lee I; OBI Pharma USA, Inc., San Diego, CA, United States., Ristoski K; OBI Pharma USA, Inc., San Diego, CA, United States., Xu D; OBI Pharma USA, Inc., San Diego, CA, United States. |
| Source: | The oncologist [Oncologist] 2026 Jul 08; Vol. 31 (8). |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42390142 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Tsimberidou+AM%22">Tsimberidou AM</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Verschraegen+C%22">Verschraegen C</searchLink>; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.<br /><searchLink fieldCode="AU" term="%22Sigal+D%22">Sigal D</searchLink>; Scripps Clinic and Scripps Cancer Center, La Jolla, CA, United States.<br /><searchLink fieldCode="AU" term="%22Lenz+HJ%22">Lenz HJ</searchLink>; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.<br /><searchLink fieldCode="AU" term="%22Hochster+H%22">Hochster H</searchLink>; Rutgers Cancer Institute, New Brunswick, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Baysal+MA%22">Baysal MA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Chakraborty+A%22">Chakraborty A</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Lee+I%22">Lee I</searchLink>; OBI Pharma USA, Inc., San Diego, CA, United States.<br /><searchLink fieldCode="AU" term="%22Ristoski+K%22">Ristoski K</searchLink>; OBI Pharma USA, Inc., San Diego, CA, United States.<br /><searchLink fieldCode="AU" term="%22Xu+D%22">Xu D</searchLink>; OBI Pharma USA, Inc., San Diego, CA, United States. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2026 Jul 08; Vol. 31 (8). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase II – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42390142 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/oncolo/oyag254 Languages: – Code: eng Text: English Titles: – TitleFull: Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Tsimberidou AM – PersonEntity: Name: NameFull: Verschraegen C – PersonEntity: Name: NameFull: Sigal D – PersonEntity: Name: NameFull: Lenz HJ – PersonEntity: Name: NameFull: Hochster H – PersonEntity: Name: NameFull: Baysal MA – PersonEntity: Name: NameFull: Chakraborty A – PersonEntity: Name: NameFull: Lee I – PersonEntity: Name: NameFull: Ristoski K – PersonEntity: Name: NameFull: Xu D IsPartOfRelationships: – BibEntity: Dates: – D: 08 M: 07 Text: 2026 Jul 08 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1549-490X Numbering: – Type: volume Value: 31 – Type: issue Value: 8 Titles: – TitleFull: The oncologist Type: main |
| ResultId | 1 |
